Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
주식 순위 #30
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the... AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
주가
$206.50
시가총액
$365.13B
변동 (1일)
-0.31%
변동 (1년)
2.58%
국가
US
거래 AbbVie Inc. (ABBV)

카테고리

AbbVie Inc. (ABBV)의 P/B 비율
March 2026 기준 P/B 비율 TTM: -119.61
AbbVie Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 -119.61입니다. 2024년 말 기준 P/B 비율은 94.54였습니다.
AbbVie Inc.의 P/B 비율 기록 (2009 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
2026 (TTM) -119.61 -100.00%
2025 0.00 -100.00%
2024 94.54 257.48%
2023 26.45 59.43%
2022 16.59 6.65%
2021 15.55 13.87%
2020 13.66 -185.13%
2019 -16.05 -4.60%
2018 -16.82 -155.55%
2017 30.28 38.22%
2016 21.91 -10.22%
2015 24.40 -59.27%
2014 59.92 220.74%
2013 18.68 16.62%
2012 16.02 237.93%
2011 4.74 31.60%
2010 3.60 0.00%
2009 0.00 0.00%
유사 기업 또는 경쟁사의 P/B 비율
회사 P/B 비율 P/B 비율 차이 국가
33.3372 -127.87%
US
6.0657 -105.07%
GB
7.1931 -106.01%
US
6.3334 -105.30%
CH
5.4725 -104.58%
US